• RWD116 The Economic Burden of Moderate to Severe Rheumatoid Arthritis (RA) in Spain: Interim 6-Month Results

    Dec 1, 2023, 00:00

  • PCR267 Health-Related Utilities Associated with Pneumococcal Disease in the Adult Population: What Do We Know?

    Dec 1, 2023, 00:00

  • PCR139 'We Have Conversations That Other Couples Don′t Have to Have:' A Qualitative Study of the Impact of Caregiving in Friedreich Ataxia (FA)

    Dec 1, 2023, 00:00

  • HPR154 When Could a Managed Entry Agreement Create a Win-Win-Win Situation - Exploring the Window of Opportunity

    Dec 1, 2023, 00:00

  • RWD174 Using Real-World Evidence to Quantify Hospital Costs of Subcutaneous Implantable Cardioverter-Defibrillator Infections in the US

    Dec 1, 2023, 00:00

  • EE62 Cost-Effectiveness of Neoadjuvant Pembrolizumab Plus Chemotherapy Followed By Adjuvant Pembrolizumab for High-Risk Early-Stage Triple-Negative Breast Cancer (ETNBC) in France

    Dec 1, 2023, 00:00

  • EE487 Cost-Effectiveness Analysis of Isavuconazole Versus Liposomal Amphotericin for the Treatment of Invasive Mucormycosis in Jordan

    Dec 1, 2023, 00:00

  • RWD87 Retrospective Observational Study of Patients with Metastatic Merkel Cell Carcinoma (mMCC) Using the Caraderm Database Linked to the French National Health Data System (SNDS)

    Dec 1, 2023, 00:00

  • PCR219 Hungarian Population Norms for the 15D Generic Preference-Accompanied Health Status Measure

    Dec 1, 2023, 00:00

  • P52 Validation of an Algorithm to Identify Lines of Therapy Among Adult Patients With Endometrial and Ovarian Cancer in a Real-World Dataset

    Dec 1, 2023, 00:00

  • EE642 The Costs of Oral Antiviral Delivery in UK Clinical Practi Expert Opinion Survey

    Dec 1, 2023, 00:00

  • EE688 Case for Clear Communication and Justification of Survival Extrapolation Methodology: A Review of NICE Submissions in Oncology

    Dec 1, 2023, 00:00

  • PT31 A Time Series Analysis of Immune Checkpoint Inhibitors Use in Italian Population: 2017-2022

    Dec 1, 2023, 00:00

  • HTA169 Highly Sensible Tactics: Strategic Insights for Navigating Highly Specialised Technology (HST) Topic Selection

    Dec 1, 2023, 00:00

  • PT5 The Role of EUnetHTA 21 in Promoting Patient Engagement

    Dec 1, 2023, 00:00

  • PCR72 How to Achieve Comprehensive Care for Breast Cancer? Challenges in Chile from the Voice of Patients

    Dec 1, 2023, 00:00

  • MT10 Clinical and Economic Impact of Point-of-Care (POC) Molecular Testing in Patients Presenting With Viral Respiratory Symptoms: A Systematic Literature Review (SLR)

    Dec 1, 2023, 00:00

  • HTA362 Being Specific About Analysis Prespecification: Challenges and Opportunities in the Context of EU HTA

    Dec 1, 2023, 00:00

  • HTA201 Knowledge Transfer and Capability Building Program on Institutionalization and Governance of HTA Ukraine: Results and Future Perspectives

    Dec 1, 2023, 00:00

  • HPR12 Assessing COA Label Claims Based on Single-Arm Trials in Rare Diseases: A Review of US FDA Labels

    Dec 1, 2023, 00:00

  • EE246 Is It Possible to Reduce the Costs of Care for Pediatric Patients With Hemophilia A and Inhibitors in Trinidad Tobago?

    Dec 1, 2023, 00:00

  • EE715 Faricimab Vs. Standard of Care in Patients with Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema: A Cost-Utility Analysis in Italy

    Dec 1, 2023, 00:00

  • EE81 Cost-Effectiveness of CDK 4/6I for the Treatment of Postmenopausal Patients With Advanced Breast Cancer HR-Positive, HER2-Negative From the Point of View of the Payer of the Public Health System in Panama

    Dec 1, 2023, 00:00

  • EE261 Economic Burden of Hemophilic Arthropathy in Patients with Hemophilia

    Dec 1, 2023, 00:00

  • MSR83 An Overview of “Multinma” Package: Multilevel Network Meta-Regression

    Dec 1, 2023, 00:00

  • HPR164 What Is a Fair Price? A Review of Definitions for Fair Prices of Health Technologies

    Dec 1, 2023, 00:00

  • EE660 Real-World Economic Burden and Healthcare Resource Utilization (HCRU) Among Patients with Triple-Class Exposed Relapsed/Refractory Multiple Myeloma (RRMM) in the United States

    Dec 1, 2023, 00:00

  • PCR259 Patient-Reported Experience Along the Psoriatic Disease Patient Journey in Portugal

    Dec 1, 2023, 00:00

  • EE438 Cost-Effectiveness of Nirsevimab Against Respiratory Syncytial Virus Lower Respiratory Tract Disease (RSV LRTD) in the US Birth Cohort

    Dec 1, 2023, 00:00

  • PCR76 Generating Health-State Utility Values in Patients Treated with Second-Line Systemic Therapy for Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)

    Dec 1, 2023, 00:00

  • HSD60 Real-World Usage of Biologic Disease-Modifying Anti-Rheumatic Drugs in Patients with Psoriatic Arthritis in Germany

    Dec 1, 2023, 00:00

  • RWD125 A Health-Related Cost and Mortality Comparison Between Early and Late-Stage Lung Cancer: A Retrospective Cohort Study from a Brazilian Health Management Organization (HMO)

    Dec 1, 2023, 00:00

  • HTA119 Mapping a Path to Standardized Evidence Quality Tools Across EU HTA Agencies and NICE: Is EU Joint Clinical Assessment Guidance Falling Behind?

    Dec 1, 2023, 00:00

  • HTA357 Cost-Comparisons, an Easier Route to NICE Recommendations?

    Dec 1, 2023, 00:00

  • EE627 The Potential Value of Identifying Type 2 Diabetes Subgroups in the CPRD Cohort for Guiding Intensive Treatment: A HTx Study Comparing Novel Data-Driven Clustering to Traditional Risk-Driven Subgroups

    Dec 1, 2023, 00:00

  • PT17 Modelling Treatment Duration in Psoriasis: Examining Extrapolation Approaches and Implications

    Dec 1, 2023, 00:00

  • PCR167 Persistence and Adherence to Insulin Treatment in Chinese Patients with Type 2 Diabetes: A Real-World Study

    Dec 1, 2023, 00:00

  • RWD100 Comparison of Real-World Safety and Effectiveness of Mepolizumab and Benralizumab in the Management of Severe Asthma: A Systematic Review

    Dec 1, 2023, 00:00

  • PCR133 Patient Experience of Second-Line Treatment for Relapsed/Refractory Chronic Lymphocytic Leukaemia in UK Clinical Practi Study Methodology

    Dec 1, 2023, 00:00

  • HTA312 The Association of ESMO-Magnitude of Clinical Benefit Scale Scores and Subsidy Decisions of Targeted Therapies for Solid Tumors in Singapore

    Dec 1, 2023, 00:00

  • PCR193 Health State Utilities Associated with X-Linked Retinitis Pigmentosa in the United Kingdom

    Dec 1, 2023, 00:00

  • SA25 Caregiver Burden in Growth Hormone Deficiency: A Targeted Review

    Dec 1, 2023, 00:00

  • HPR123 Risk Sharing Agreements in the Asia-Pacific Region: A Systematic Literature Review on New Pricing Modalities to Improve Value Access

    Dec 1, 2023, 00:00

  • EE444 Cost-Effectiveness Analysis of Replacing PCV13 with PCV15 in the Pediatric National Immunization Program of Greece

    Dec 1, 2023, 00:00

  • EPH69 Disease Burden of Patients With Antibiotic-Resistant Bacteria (Extended-Spectrum Beta-Lactamase or Carbapenem-Resistant Enterobacteriaceae) in Korea

    Dec 1, 2023, 00:00

  • PT26 How Aware Are Biotech and Pharmaceutical Companies of the Implementation of the New EU HTA?

    Dec 1, 2023, 00:00

  • HSD55 Sex Differences in Guideline Adherence for Coronary Angiography in Patients with Suspected Chronic Coronary Artery Disease in Germany: Insights from the ENLIGHT-KHK Trial

    Dec 1, 2023, 00:00

  • RWD172 Strategies for the Rational Use of Biologic Therapies in an Integrated Clinic for Immune-Mediated Skin Diseases

    Dec 1, 2023, 00:00

  • RWD171 Healthcare Resource Utilization and Cost of Renal Replacement Therapy in Brazil: A Five-Year Procedure-Level Analysis

    Dec 1, 2023, 00:00

  • HTA345 Amplifying the Patient Voi Characterising the Impact of Patient and Clinician Engagement (PACE) Meetings on SMC Decision Making

    Dec 1, 2023, 00:00

  • Disclosure Information

    Dec 1, 2023, 00:00

  • EPH174 Trends in Hospitalization of Patients with Wilson's Disease in Germany

    Dec 1, 2023, 00:00

  • CO105 A Retrospective Study Characterizing Age at Loss of Ambulation Among Patients With Friedreich Ataxia Using Health Administrative Claims Data in the United States

    Dec 1, 2023, 00:00

  • EPH163 Dental Preventive Examinations and Caries Prevalence in Children Aged 8-14 Years

    Dec 1, 2023, 00:00

  • HTA358 Value-Based Contracts Types Across Global Healthcare Systems: Comparing Perceptions Between Finance-Based and Outcomes-Based Agreements

    Dec 1, 2023, 00:00

  • HSD37 Gender Disparities in Treatment and Costs of Rectal Cancer at the End of Life Phase—An Analysis of German Claims Data

    Dec 1, 2023, 00:00

  • HTA282 Evolution of Timeframes Within the Overall Time-to-Market Since Marketing Authorisation for New Innovative-Presumed Products in France Since the First Published Economic Opinion

    Dec 1, 2023, 00:00

  • PCR181 Health-Related Quality-of-Life of Patients Treated with Repotrectinib for Neurotrophic Tyrosine Receptor Kinase (NTRK)-Positive Advanced Solid Tumors: Results from TRIDENT-1

    Dec 1, 2023, 00:00

  • HSD64 Breast Cancer in the COVID-19 Pandemic Era: An Old Tool with Modern Innovations

    Dec 1, 2023, 00:00

  • EE618 Sacubitril/Valsartan Vs Enalapril Use in Hospitalized Patients with Heart Failure in Spain

    Dec 1, 2023, 00:00

  • EE477 Exploring the Perceived Value of Fixed-Dose Combinations in Type 2 Diabetes Mellitus in the EU4 and the UK

    Dec 1, 2023, 00:00

  • PCR7 People Living With HIV’s Lived Experiences of Long-Acting Injectable Antiretroviral Treatment Administrations in France Show the Central Role of Hospital Nurses in Care: A Qualitative Study (PANTER)

    Dec 1, 2023, 00:00

  • HTA223 Comparative Evaluation of the HTA Evidence Requirements and Outcomes for Digital Health Technologies in Germany and UK

    Dec 1, 2023, 00:00

  • EPH81 Clinical Characteristics and Treatment Patterns of Patients With Early-Stage Non-Small Cell Lung Cancer (NSCLC)

    Dec 1, 2023, 00:00

  • Organizational Practices

    Dec 1, 2023, 00:00

  • MSR20 Estimating Undetected Medication Errors at Care Transitions: A Framework to Support Decision-Making

    Dec 1, 2023, 00:00

  • EE238 Cost-Effectiveness of Online Cognitive Behavioral Therapy for Children with Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (CFS/ME) Compared to Online Activity Management: FITNET-NHS Trial Findings

    Dec 1, 2023, 00:00

  • HSD104 Comparative Analysis of Legislations and Market Access of Cannabis Medicines in Poland and Ukraine

    Dec 1, 2023, 00:00

  • HTA353 Analysis of the Impact of Early Access Decisions on Pricing and Reimbursement Decisions in France

    Dec 1, 2023, 00:00

  • EPH78 A Review of Patient-Reported Outcomes and External Control Arms in Regulatory Submissions of Novel Oncology Drugs

    Dec 1, 2023, 00:00

  • PCR92 The Experience and Utilization of Patient Reported Outcomes (PROs) in Leber’s Hereditary Optic Neuropathy (LHON): A Targeted Literature Review

    Dec 1, 2023, 00:00

  • HSD125 Non-Dispensed Prescriptions from the Public and Private Health Care Sectors: A Comparative Register Study

    Dec 1, 2023, 00:00

  • EE148 Are General Population Utilities Appropriate to Use as Baselines for Age-Adjustment of Utility Values?

    Dec 1, 2023, 00:00

  • HTA321 Factors Influencing the Shi Costs of Orphan Drugs After Their Renewed Regular Benefit Assessment Due to Exceeding the Sales Threshold in Germany

    Dec 1, 2023, 00:00

  • HTA342 Real World Evidence in German HTA: The Challenges of Comparative Routine Practice Data Collection (ABD) for Early Benefit Assessment (AMNOG)

    Dec 1, 2023, 00:00

  • CO17 How to Assess Nationwide Population-Based Clinical Benefit of Treatments Using Public Information? Immunotherapies Case Study

    Dec 1, 2023, 00:00

  • HSD7 Longitudinal Analysis of Diagnostic Procedures for Sleep Disorders in the German In-Patient Sector

    Dec 1, 2023, 00:00

  • PT32 Cost-Effectiveness of Lorlatinib in Second-Line Treatment of ALK-Positive Advanced Non-Small Cell Lung Cancer in China

    Dec 1, 2023, 00:00

  • RWD142 Global Use of Nordic Real-World Eviden A Systematic Review of Published Literature and HTA Submissions

    Dec 1, 2023, 00:00

  • MSR16 Health-Related Quality of Life Multi-Instrument Comparison for the Use in Children Aged 2-4 Years Old

    Dec 1, 2023, 00:00

  • EE707 Modelling the Cost Effectiveness and Budget Impact of Uterine Botulinum Toxin Injections in Severe Dysmenorrhoea: A France Perspective

    Dec 1, 2023, 00:00

  • PCR36 Building a COA Strategy in Allergic Fungal Rhinosinusitis: Patient Experiences and Clinical Outcome Assessments from the Literature

    Dec 1, 2023, 00:00

  • CO182 Efficacy of Venetoclax+Obinutuzumab+Ibrutinib Compared to Alternative Therapeutic Options in the First-Line Treatment of Chronic Lymphocytic Leukemia (Fit Population): A Systematic Review and Network Meta-Analysis

    Dec 1, 2023, 00:00

  • EE10 Cost Effectiveness of Implantable Cardioverter Defibrillator Therapy Versus Drug Therapy in Patients for 1.5 Primary Prevention in China: An Analysis Using the Improve SCA Study

    Dec 1, 2023, 00:00

  • EPH147 The Costs of Unaddressed Hearing Loss in Chilean Children with Bilateral Microtia and External Auditory Canal Atresia and Cost Effectiveness of Different Treatment Interventions

    Dec 1, 2023, 00:00

  • EPH215 Informal Caregiving and Illicit Drug Use in England and Wales

    Dec 1, 2023, 00:00

  • EE470 Comparing Three Indirect Cost Approaches in the IQVIA Core Diabetes Model

    Dec 1, 2023, 00:00

  • PCR173 Identifying Behaviors Practiced By Individuals to Avoid COVID-19: Development of the Content of the Physical Distancing Scale – COVID-19 (PDS-C19)

    Dec 1, 2023, 00:00

  • PCR149 Determination of Ranges of HiSQOL Scores Defining Clinically Meaningful Within-Patient Improvement Thresholds and Severity Levels

    Dec 1, 2023, 00:00

  • Health Service Delivery Process of Care

    Dec 1, 2023, 00:00

  • MSR97 Performance of Matching Adjusted Indirect Comparisons for Single-Arm Trials: A Simulation Study

    Dec 1, 2023, 00:00

  • HPR53 Timely Reimbursement: The Impact of Early Access Programmes in Non-Squamous Non-Small Cell Lung Cancer

    Dec 1, 2023, 00:00

  • EE683 The Impact of Tumor Treating Fields (TTFields) Therapy Usage on Cost-Effectiveness: An Analysis of the Incremental Cost-Effectiveness Ratio (ICER)

    Dec 1, 2023, 00:00

  • MSR81 When Should I Mix? Improving Understanding of the Predictive Behavior of Mixture-Cure Survival Models Informed by Immature Data

    Dec 1, 2023, 00:00

  • EE233 Alternatives to Bayesian Network Meta-Analysis in Case of Proportional Hazards Invalidity: Review of HAS Cost-Utility Studies Opinions in France

    Dec 1, 2023, 00:00

  • MSR78 Use of External Control Data to Adjust for Treatment Switching in Cost-Effectiveness Analyses: Lisocabtagene Maraleucel (Liso-Cel) Versus Standard of Care (SOC) in Second-Line Relapsed or Refractory Large B-Cell Lymphoma

    Dec 1, 2023, 00:00

  • EE87 Liquid Metformin for Pediatric Patients with Metabolic Syndrome at Risk of Developing DMT2: Cost-Effectiveness Analysis in Mexican Public Health Institutions

    Dec 1, 2023, 00:00

  • PCR226 Health Related Quality of Life and Health Utility Values Across Different Levels of Physically Distancing Behaviors to Avoid COVID-19 in Immunocompromised Adults – The Eagle Study

    Dec 1, 2023, 00:00

  • EE720 Budget Impact of Preoperative Anemia Management, the First Pillar of Patient Blood Management, on the Romanian Healthcare System

    Dec 1, 2023, 00:00

  • MSR32 Tips for Excel(lent) Modelling or R There Better Alternatives?

    Dec 1, 2023, 00:00

  • SA63 Planning Phase 3 Clinical Trials More Efficiently Using an Evidence-Mapping Approach

    Dec 1, 2023, 00:00

  • EE580 New Anti-CGRP in Fran Estimated Financial Impact of Eptinezumab in Hospitals, a Prospective Stake

    Dec 1, 2023, 00:00

  • EE228 Cost to Society and Financial Toxicity Related to Personalized Oncology Treatment in Bulgaria

    Dec 1, 2023, 00:00

  • HTA285 The Impact of the Disease Severity Modifier on NICE Technology Appraisal Decisions

    Dec 1, 2023, 00:00

  • HPR105 Profitability in the Global Pharmaceutical Industry: A Contested Space

    Dec 1, 2023, 00:00

  • HTA135 Uncertainty in AMNOG Benefit Assessments: Reflection of G-BA's Underlying Motivation to Cause AbD

    Dec 1, 2023, 00:00

  • PT12 Perceived Financial Burden and Quality of Life Among Patients with Cancer

    Dec 1, 2023, 00:00

  • HPR136 Designing an Effective Bundle Payment Program for Osteoarthritis

    Dec 1, 2023, 00:00

  • HTA79 CADTH Reimbursement Recommendations for Mental Illness Health Products: 10-Year Trends in Relation to Non-Mental Illness Health Products and Recommendations From Other HTA Bodies

    Dec 1, 2023, 00:00

  • PCR196 Factors Associated with Behaviors Measured By the Rett Syndrome Behavior Questionnaire in Rett Syndrome

    Dec 1, 2023, 00:00

  • RWD127 Systemic Treatment of Non-Melanoma Skin Cancers in Fran Real-World Analysis Using French Data from the National Hospitalization Database

    Dec 1, 2023, 00:00

  • EE216 Provision and Public Expenditure of Radiotherapy Services in Greece (2013-2020)

    Dec 1, 2023, 00:00

  • EE584 Is Point-of-Care Testing in Emergency Departments Cost-Effective? A Systematic Literature Review

    Dec 1, 2023, 00:00

  • MSR25 Uncertain About Uncertainty in Matching-Adjusted Indirect Comparisons (MAIC)? A Simulation Study to Compare Methods for Variance Estimation

    Dec 1, 2023, 00:00

  • MSR70 Translation, Cross-Cultural Adaptation, and Psychometric Evaluation of the Brief Illness Perception Questionnaire Into Yoruba Language Among Persons With Chronic Low Back Pain

    Dec 1, 2023, 00:00

  • EE97 Budget Impact Analysis with and without Performance-Based Managed Entry Agreement (PBMEA) of Different Treatments for Spinal Muscular Atrophy (SMA) in the Kingdom of Saudi Arabia

    Dec 1, 2023, 00:00

  • HPR211 Turkiye Healthcare Inflation Review between 2017 to 2022

    Dec 1, 2023, 00:00

  • RWD147 Real-World Data of Therapeutic Inertia in Diabetes in a Health Care Intitution

    Dec 1, 2023, 00:00

  • CO70 COPD Exacerbations Pre, During, and Post COVID-19 Pandemic in the US

    Dec 1, 2023, 00:00

  • HTA308 Market Access for Anti-Cancer Drugs: Is the Demonstration of a Clinical Benefit on Survival Correlated With Price Level?

    Dec 1, 2023, 00:00

  • PCR55 Unleashing the Power of Social Media Listening: A Promising Tool for Patient-Focused Research

    Dec 1, 2023, 00:00

  • EPH185 Healthcare Resource Utilization and Cost Burden Assessment of Patients with Myasthenia Gravis in Denmark, Finland, and Sweden

    Dec 1, 2023, 00:00

  • EE309 Cost-Effectiveness of Mavacamten for the Treatment of Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy in the Netherlands

    Dec 1, 2023, 00:00

  • EE31 Economic Burden of Hospitalized Respiratory Syncytial Virus Infection Among Children in Spain, 2016–2019

    Dec 1, 2023, 00:00

  • PCR68 Estimation of Minimal Clinically Important Difference (MCID) for the Tardive Dyskinesia Impact Scale (TDIS), a Tardive Dyskinesia-Specific Patient-Reported Outcome

    Dec 1, 2023, 00:00

  • HTA2 Cost-Effectiveness of a Clinical Care Pathway for the Screening of Nonalcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus

    Dec 1, 2023, 00:00

  • EPH117 The Phollow Cohort: Real-World Therapeutic Adherence to Blood Glucose-Lowering Drugs (EXCLUDING INSULINS) in Portugal

    Dec 1, 2023, 00:00

  • PCR85 Facilitating the Identification of Appropriate Patient-Centered Outcome Measures (PCOMS) in Rare Disease (RD) Clinical Research Using Functional Impacts Matching

    Dec 1, 2023, 00:00

  • HTA250 Mapping the VF-14 Onto the EQ-5D-5L: The Potential to Estimate Quality-Adjusted Life-Years Without Generic Quality-of-Life Data in Ophthalmology

    Dec 1, 2023, 00:00

  • EPH251 Subtype Distribution of Amyloidosis in the United States: Insights from an Electronic Health Records Database Analysis

    Dec 1, 2023, 00:00

  • EE358 A Systematic Literature Review of Reviews Related to the Impacts of Catastrophic Health Expenditures Related to Cancer Care

    Dec 1, 2023, 00:00

  • SA14 "I've Got a Text!” Feedback from Prospective Participants on the Use of SMS Surveys in Real-World Studies

    Dec 1, 2023, 00:00

  • HSD95 Unmet Needs and Value Proposition for Genital Warts Novel Treatments: Payer Perception

    Dec 1, 2023, 00:00

  • HSD25 Patients’ Satisfaction from Primary Healthcare Services in 1ST Local Health Unit (LHU) of N. Philadelphia-N. Chalkidona Municipality Greece

    Dec 1, 2023, 00:00

  • EE154 Cost-Effectiveness of Transcatheter Aortic Valve Intervention (TAVI) as Compared with Surgical Aortic Valve Intervention (SAVR) in Swedish Low Risk Aortic Stenosis Patients: Evidence Using Swedeheart Registry Data (2018-2020)

    Dec 1, 2023, 00:00

  • EE518 An Updated Cost-Effectiveness Analysis of Axicabtagene Ciloleucel in Second-Line Large B-Cell Lymphoma Patients in the United States

    Dec 1, 2023, 00:00

  • EE498 Cost-per-Responder Analysis of Bimekizumab Vs Other Licensed Anti-Interleukin Therapies in Psoriatic Arthritis from a UK Perspective

    Dec 1, 2023, 00:00

  • Expanding Data Sources: Creative Use of Data in Health Economics Analyses

    Dec 1, 2023, 00:00

  • PCR236 Treatment Preferences Among Patients With Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) in France, Germany, Italy, Japan, Spain, the United States, and the United Kingdom

    Dec 1, 2023, 00:00

  • EE80 Cost-Effectiveness of Ribociclib Plus a Non-Steroidal Aromatase Inhibitor for the Treatment of Pre- and Peri-Menopausal Women with HR+/HER2 Advanced Breast Cancer in Turkey

    Dec 1, 2023, 00:00

  • EE86 Healthcare Resource Utilization (HCRU) and Associated Costs Among Patients with Acute Myeloid Leukemia (AML) Treated with Oral Azacitidine as Maintenance and Those Eligible but Not Treated Using a US Claims Database

    Dec 1, 2023, 00:00

  • EE124 Analysis of the Use of the Haute Autorité De Santé (HAS) Opinions by Hospital Pharmacists in France

    Dec 1, 2023, 00:00

  • MT49 Cost-Effectiveness Analysis of Farapulse™ Pulsed Field Ablation (PFA) in Patients with Paroxysmal Atrial Fibrillation

    Dec 1, 2023, 00:00

  • EE628 Cost of Basal Insulin Therapy in Fran An Observational Longitudinal Study

    Dec 1, 2023, 00:00

  • MSR35 Beyond HbA1c: A Contemporary Approach to Modelling Type 2 Diabetes Within the Updated Cardiff T2D Model

    Dec 1, 2023, 00:00

  • HPR75 What Percent of the Growth in Annual French Social Health Insurance Budget Is Attributed to New Health Products? An Estimation Based on a Retrospective Review of Budget Impact Analyses

    Dec 1, 2023, 00:00

  • EE569 Cost-Effectiveness of Eftrenonacog Alfa in Treatment of Severe Haemophilia B Patients in Turkey

    Dec 1, 2023, 00:00

  • RWD101 Intravitreal Therapies and Their Patterns of Use in Lombardy Region

    Dec 1, 2023, 00:00

  • EE513 Cost-Effectiveness of Axicabtagene Ciloleucel and Tisagenlecleucel for Relapsed or Refractory Large B-Cell Lymphoma—Exploring the Impact of Country Settings and Performance-Based Managed Entry Agreements

    Dec 1, 2023, 00:00

  • PCR224 Corticosteroids Usage Impact on Inflammatory Bowel Disease Patients, in Portugal

    Dec 1, 2023, 00:00

  • P36 Towards a Collaborative Value Assessment Framework for Provider-Facing Digital Health Technologies Used in Chronic Disease Management: Findings and Implications

    Dec 1, 2023, 00:00

  • HPR118 The Assessment of Alternative or Abbreviated Market Access Pathways for Pharmaceutical Reimbursement in 13 European Markets

    Dec 1, 2023, 00:00

  • OP10 The Ripple Effects of Healthcare Reforms in Germany: A Reduced Free Pricing Period

    Dec 1, 2023, 00:00

  • MSR11 Performance of Progression-Based and Time-to-Death Utility Analysis Methods and Their Implications on Economic Models: A Targeted Review

    Dec 1, 2023, 00:00

  • HTA210 Characteristics and Outcomes of Health Technology Assessment Submissions for Advanced Therapy Medicinal Products in Europe: Perspective From Non-EU5 Countries

    Dec 1, 2023, 00:00

  • P40 Man Versus Machine: Can AI-Assisted Technology be Used to Support the Development of Economic Models?

    Dec 1, 2023, 00:00

  • HTA196 HTA Guidance Updates and Usage of Real-World Evidence (RWE) in Reimbursement Decisions—A 2023 Perspective

    Dec 1, 2023, 00:00

  • PT9 Harnessing the Potential of Natural-Language Processing and Interconnected Data Streams for Complex Diseases in the Hospital Setting: Lupus Case Study in France (LUPUS REAL)

    Dec 1, 2023, 00:00

  • PCR233 Socioeconomic Impact of Muscular Dystrophies on Patients and Their Caregivers in the Czech Republic

    Dec 1, 2023, 00:00

  • PCR125 Unmet Needs of People with Multiple Sclerosis: Findings for an Improvement of the Patient Journey in Portugal

    Dec 1, 2023, 00:00

  • EE155 Economic Burden of Obstructive Hypertrophic Cardiomyopathy in France

    Dec 1, 2023, 00:00

  • HSD94 Assessing Payer Perspectives on Novel Therapies for the Treatment of Gorlin Syndrome

    Dec 1, 2023, 00:00

  • EE384 Indirect Cost of HPV-Attributable Cancer in the United Kingdom

    Dec 1, 2023, 00:00

  • MSR22 Standardized Contrasts Across Trials in Individual Patient Data Meta-Analysis With Time-to-Event Outcomes

    Dec 1, 2023, 00:00

  • RWD20 Health Care Resource Utilization Patterns in Finnish Multiple Myeloma Patients: A Population-Based Cohort Study

    Dec 1, 2023, 00:00

  • HSD68 Emotions of Physicians Elicited by Their Patients’ Rare Disease Diagnoses: A Cross-Sectional Study in Europe and the United States

    Dec 1, 2023, 00:00

  • HTA234 How Long Is the Weight? A Framework for Linear Interpolation of the National Institute for Health and Care Excellence (NICE) Severity Weighting in the Context of Probabilistic Sensitivity Analysis (PSA): A Case Study

    Dec 1, 2023, 00:00

  • PCR216 Patient-Driven Outcome Selection (PDOS): A Patient-Focused Approach for Selecting Outcomes Using Patient-Generated Data

    Dec 1, 2023, 00:00

  • MSR24 Shaping the Value Equation in Digital Healthcare: A Holistic Perspective on Patient, System, and Provider Interactions

    Dec 1, 2023, 00:00

  • EE668 Cost-Effectiveness of Pembrolizumab as an Adjuvant Treatment for Adults and Adolescents Aged 12 Years and Older With Resected Stage IIB/IIC Melanoma in France

    Dec 1, 2023, 00:00

  • SA76 Systematic Literature Review on Economic Burden of Retinitis Pigmentosa (RP) and Visual Impairment in France

    Dec 1, 2023, 00:00

  • EE630 The Economic Burden of Obesity in 4 Selected South-Eastern European Countries: Healthcare Resource Use and Costs Associated with Obesity-Related Comorbidities

    Dec 1, 2023, 00:00

  • MSR127 How to Estimate 95% Confidence Intervals When Combining Bootstrapping and Multiple Imputation in Economic Evaluations: A Simulation Study

    Dec 1, 2023, 00:00

  • PT6 What Do Patients Value? Development of a Preference-Based Health Utility Score for Chronic Obstructive Pulmonary Disease (COPD)

    Dec 1, 2023, 00:00

  • HTA323 Analyzing Historic Health Technology Assessments (HTAs): Surrogate Endpoints (SEs) in the Interstitial Pneumonia With Autoimmune Features (IPF)/Interstitial Lung Disease (ILD) Therapeutic Domain

    Dec 1, 2023, 00:00

  • EE710 The Environmental, Healthcare, and Societal Impact of Asthma Pathway in the UK: A Cost-of-Illness Study

    Dec 1, 2023, 00:00

  • PCR172 Physical Distancing to Avoid COVID-19 and the Association With Humanistic Burden in Immunocompromised Adults – The Eagle Study

    Dec 1, 2023, 00:00

  • SA19 Biologics Sequencing in Clinical Units (BISCUITS): UK IBD Registry Agile Research

    Dec 1, 2023, 00:00

  • EE247 Emicizumab is Cost-Saving for Finnish Hemophilia A Patients with Factor VIII Inhibitors

    Dec 1, 2023, 00:00

  • EE673 Cost-Effectiveness Analysis of Pembrolizumab for First-Line Treatment in Patients With Persistent, Recurrent, and Metastatic Cervical Cancer in the United States: Results From the Final Analysis of Trial

    Dec 1, 2023, 00:00

  • MT21 Clinical Application of Circulating Tumor Cells in Melanoma Patients: Overview of Current Available Data

    Dec 1, 2023, 00:00

  • PCR10 A Comparative Study of Health-Related Quality-of-Life Outcomes in Patients Undergoing Total Hip Arthroplasty in the Hungarian Public and Private Healthcare

    Dec 1, 2023, 00:00

  • SA70 Clinical Benefits and Cost-Effectiveness of High-Dose Capsaicin Cutaneous Patches for Peripheral Neuropathic Pain: A Literature Review

    Dec 1, 2023, 00:00

  • HSD10 The Hospital Care Pathway of Patients Treated By Axi-Cel and Tisa-Cel between 2018 and 2021 in Fran A National Study Based on the Comprehensive Inpatient Stays Database

    Dec 1, 2023, 00:00

  • EE558 The Cost-Effectiveness of Budesonide/Formoterol Maintenance and Reliever Therapy Versus Salmeterol/Fluticasone Plus As-Needed Salbutamol Among Asthma Patients ≥12 Years in China

    Dec 1, 2023, 00:00

  • RWD10 Real-World Safety and Effectiveness of Sodium Oxybate in the Management of Narcolepsy: A Systematic Literature Review

    Dec 1, 2023, 00:00

  • EPH55 The Prevalence and Comorbidities of Prurigo Nodularis – A Danish Register-Based Study From 1995 to 2021

    Dec 1, 2023, 00:00

  • CO32 Validation of a Scoring Algorithm for the Clinician-Reported Outcome ”Prurigo Activity and Severity (PAS)’’ Tool: Results Based on Clinical Studies of Dupilumab in Adults with Prurigo Nodularis

    Dec 1, 2023, 00:00

  • CO42 4P Care and Adjusting Therapy for Hypothyroidism – A Potential to Reduce Costs of Healthcare and Loss of Productivity

    Dec 1, 2023, 00:00

  • HTA363 Impact of ASMR Changes on List Prices: An Analysis of HAS Re-Evaluations

    Dec 1, 2023, 00:00

  • RWD29 Development of a Comprehensive List of Immunosuppressive Therapies to Enable a Multi-Data Source Global Real-World Effectiveness (RWE) Program of Immunocompromised Patients

    Dec 1, 2023, 00:00

  • PCR158 The Uniqueness and Overlap of the EQ-HWB and the EQ-5D-5L in Four Diseases, Healthy Subjects, and Caregivers

    Dec 1, 2023, 00:00

  • HPR120 Investigating the Nature and Scope of Innovative Payment and Pricing Schemes for Health Technologies

    Dec 1, 2023, 00:00

  • PT13 An Evaluation of the Impact of Evidence Grouping on Certainty Rating When Performing a Grade Assessment Without a Meta-Analysis

    Dec 1, 2023, 00:00

  • CO121 Prevalence of Musculoskeletal and Renal Outcomes in Patients With Chronic Hepatitis B Undergoing Antiviral Treatments in a Real-World Setting

    Dec 1, 2023, 00:00

  • Using Artificial Intelligence to Enhance Efficiency in Systematic Reviews and Meta-Analyses

    Dec 1, 2023, 00:00

  • EPH53 Leave or Stay? Influencing Factors of Intention to Leave or Stay in Healthcare Profession After Coronavirus Pandemic Among Frontline Nurses

    Dec 1, 2023, 00:00

  • HTA24 Are the Hurdles Too High for Access to Gene Therapies in the UK?

    Dec 1, 2023, 00:00

  • EE545 Evaluating the Clinical Burden of Disease and Costs of ANCA-Associated Vasculitis in Spain: Main Findings from the EUVAS Based Registry.

    Dec 1, 2023, 00:00

  • RWD8 Study of the Mental Health of Pharmacists During Wartime in Ukraine

    Dec 1, 2023, 00:00

  • PCR270 Development of a Quality Appraisal Tool for Systematic Literature Reviews of Studies Eliciting Health State Utility Values (HSUVs): A Delphi Consensus Approach

    Dec 1, 2023, 00:00

  • EE298 Process and Results of the Third Update of the Dutch Guideline for Economic Evaluations in Healthcare: Evolution Instead of Revolution

    Dec 1, 2023, 00:00

  • CO107 Resource Use Associated with Alpelisib for the Treatment of Patients with PROS: A Modeling Approach

    Dec 1, 2023, 00:00

  • EPH123 A Machine Augmented Systematic Literature Review: Prevalence of Coinfections in COVID-19 Patients During Early and Late Pandemic Periods

    Dec 1, 2023, 00:00

  • EE255 The Budget Impact of Switching From High to Low Carbon Emission Inhalers in England

    Dec 1, 2023, 00:00

  • EE226 Economic Evaluation of Trastuzumab in HER2-Positive Early Breast Cancer in Indonesia: A Cost-Effectiveness Analysis

    Dec 1, 2023, 00:00

  • EE743 Cost Utility Analysis of Influenza Vaccine Among People Aged 50 Years and Older Living with Comorbidities in Egypt

    Dec 1, 2023, 00:00

  • HSD99 Analysis of Evidence Information About Herbal Medicinal Products and Its Use for Postgraduate Pharmacy Trainings in Ukraine

    Dec 1, 2023, 00:00

  • EE281 Predicted UK Health Care Associated Cost-Savings and Health-Related Quality of Life Benefits of Introducing a Digital Leakage Notification System for People Living with a Stoma

    Dec 1, 2023, 00:00

  • CO154 Evaluating Patients Perception of Generic Medicines in Greece

    Dec 1, 2023, 00:00

  • MSR45 Evaluation of the Future Impact of Immuno-Oncology Introduction on Cancer Mortality in Italy

    Dec 1, 2023, 00:00

  • EE40 Cost-Effectiveness Analysis of Tofacitinib for the Treatment of Active Ankylosing Spondylitis in Greece

    Dec 1, 2023, 00:00

  • EPH58 The Risk of First and Recurrent Mace Associated with Elevated Lp(A) in a Primary Prevention Population

    Dec 1, 2023, 00:00

  • HSD102 Preferences of Nurses for Attributes of Pediatric Hexavalent Vaccines in the United Kingdom

    Dec 1, 2023, 00:00

  • HSD30 Real-World Prescribing of GLP-1s Among Patients With Overweight or Obesity in the United States

    Dec 1, 2023, 00:00

  • EPH263 Algorithmic Public Health? The Path Towards AI-Assisted Health Promotion

    Dec 1, 2023, 00:00

  • EE571 Indirect Costs and Out-of-Pocket Expenses of Chronic Kidney Disease on Dialysis in Bogota, Colombia

    Dec 1, 2023, 00:00

  • EE142 Healthcare Resource Use and Costs Associated with Herpes Zoster/Post-Herpetic Neuralgia Episodes in Italy: A Retrospective Observational Study

    Dec 1, 2023, 00:00

  • Reviewer Acknowledgment

    Dec 1, 2023, 00:00

  • HPR35 Modelling the Effects of Smoking on Healthy Life Expectancy (HLE) in England

    Dec 1, 2023, 00:00

  • EE734 Cost Consequences of Using Clevidipine in Cardiac Surgery from the Perspective of a US Hospital

    Dec 1, 2023, 00:00

  • HPR99 Regional Access Timelines in Italy: Factors Affecting Speed and Equity

    Dec 1, 2023, 00:00

  • HTA302 A Retrospective Analysis of the Impact of Treatment Effect on HTA Outcomes for Oncology Treatments Assessed in France and Germany

    Dec 1, 2023, 00:00

  • EPH59 An Evidence Gap Analysis of the Epidemiology and Burden of Obstructive Hypertrophic Cardiomyopathy

    Dec 1, 2023, 00:00

  • EPH170 Epidemiology of Stroke in Bulgaria

    Dec 1, 2023, 00:00

  • PCR59 Self-Reported Health Status and Its Predictors Among People with Diabetes in France

    Dec 1, 2023, 00:00

  • EE143 Cost-Effectiveness of Replacing the Sequence PCV13→PPV23 with PCV20 in the French Adult Pneumococcal Vaccination Program

    Dec 1, 2023, 00:00

  • RWD80 Labor Impact in Patients with Rheumatoid Arthritis (RA) Treated with Advanced Therapies

    Dec 1, 2023, 00:00

  • RWD145 Devastating Loss of Life Expectancy and Quality-Adjusted Life Years after Stroke in Brazil: A Focus on Hemorrhagic Subtypes

    Dec 1, 2023, 00:00

  • PT40 Epidemiology and Burden of Illness of Lupus in Children by Form of Lupus: A Retrospective Longitudinal National Hospital Claims Study in France

    Dec 1, 2023, 00:00

  • HTA85 Will the New Dutch Criteria for Therapeutic Value for Oncology Drugs Create Inequalities in Access between Countries? a Review of Health Technology Assessment Oncology Submissions.

    Dec 1, 2023, 00:00

  • HPR201 Lessons from the COVID-19 Vaccines Taskforce

    Dec 1, 2023, 00:00

  • EE744 Invasive Meningococcal Disease Economic Burden: A Comprehensive Analysis

    Dec 1, 2023, 00:00

  • PCR154 How and Why Do Multimorbid Patients Adhere to Their Medications? A Qualitative Study Looking Beyond the Risk-Benefit Scale

    Dec 1, 2023, 00:00

  • PCR260 Influence of Disease Activity and Angioedema on EQ-5D-5L Utility Scores in Chronic Spontaneous Urticaria

    Dec 1, 2023, 00:00

  • HTA301 How End of Life Translates to Severity Weighting Under the New National Institute for Health and Care Excellence (NICE) Methodology. A Review of Past Oncology Appraisals

    Dec 1, 2023, 00:00

  • OP19 Monoclonal Antibodies in Oncology: A Comparative Analysis of Subcutaneous Form Use Between Paris University Hospitals (AP-HP) Versus French Hospitals

    Dec 1, 2023, 00:00

  • MSR86 Use of Data Linkage for the Evaluation of Medical Devices: A Systematic Literature Review

    Dec 1, 2023, 00:00

  • HTA172 Value of French Framework for Early Access Programs for the HTA Appraisal in the Rare Disease Spa The Example of Lanadelumab in Patients With Hereditary Angioedema

    Dec 1, 2023, 00:00

  • HTA359 Market Access of ATMPs in Fran Challenges and Opportunities

    Dec 1, 2023, 00:00

  • EE301 Consumption Value of a Quality-Adjusted Life Year: A Time Trade-Off for Income Analysis of Hungarian Cross-Sectional Data

    Dec 1, 2023, 00:00

  • SA67 Considerations for Including Different Routes of Administration in Network Meta-Analysis: A Comprehensive Review

    Dec 1, 2023, 00:00

  • EPH30 Impact of Paternal Treatment on Birth Outcomes Among Individuals with Autoimmune Rheumatic Diseases

    Dec 1, 2023, 00:00

  • HPR119 Assessing Health Policies in Turkiye: Expert Insights on Current Challenges and Policy Recommendations from Written Motions

    Dec 1, 2023, 00:00

  • EPH120 Explaining the Differences in Social Distancing Behavior in the EU During the COVID-19 Pandemic

    Dec 1, 2023, 00:00

  • EE560 A Comparison of Time-Driven Activity-Based Costs for Patients and Caregivers Receiving Intravitreal Treatments for Neovascular Age-Related Macular Degeneration

    Dec 1, 2023, 00:00

  • SA5 Innovative Direct-to-Physician Retrospective Chart Review Approach: Synthesized Learnings from Completed and Ongoing

    Dec 1, 2023, 00:00

  • HTA188 The Potential Value of Health Technologies Postponing Total Knee Replacements While Increasing Patients’ Quality of Life

    Dec 1, 2023, 00:00

  • CO9 Post-Discharge Mortality in Patients with Mental Illness Hospitalized Compulsorily in Accordance with the Provisions of Article 29 of the Japanese Mental Health and Welfare Law

    Dec 1, 2023, 00:00

  • CO138 Outcomes and Health-Related Costs of Patients with Unresectable Stage III Non-Small Cell Lung Cancer in the Brazilian Public Health System

    Dec 1, 2023, 00:00

  • EE35 Social and Economic Burden of Hepatitis C in Russia

    Dec 1, 2023, 00:00

  • PCR100 Vascular Access Adverse Events: A Comprehensive Literature Review and Comparative Analysis

    Dec 1, 2023, 00:00

  • HTA225 New HTA Model for Digitally Supported Managed Care: Lessons From Parkinson's Disease

    Dec 1, 2023, 00:00

  • HTA127 No Half Measures: Health Inequalities in Technology Appraisal

    Dec 1, 2023, 00:00

  • HPR138 How Are Patient Experience Data Reported in Regulatory Evaluation of Medicinal Products? A Document Analysis of European Public Assessment Reports

    Dec 1, 2023, 00:00

  • Study Approaches

    Dec 1, 2023, 00:00

  • HPR56 Rare Disease Policies and Orphan Drug Designation Processes in European and Asia-Pacific (APAC) Countries

    Dec 1, 2023, 00:00

  • EPH62 Impact of Ethnicities on the Risk of Type 2 Diabetes in Women With a History of Gestational Diabetes: Results of a Systematic Review and Meta-Analysis

    Dec 1, 2023, 00:00

  • EPH67 Epidemiology and Economic Burden of Tick-Borne Encephalitis Hospitalizations in Mainland Fran 2014-2021 Analysis of the PMSI Database

    Dec 1, 2023, 00:00

  • HTA365 Comparison of the Use of Real-World Evidence for Clinical Effectiveness in HTA Pre- and Post- Introduction of the NICE Framework

    Dec 1, 2023, 00:00

  • EE43 Utilizing Real-World Evidence to Estimate Treatment Costs Among Norwegian Patients with Myasthenia Gravis Treated with Intravenous Immunoglobulin (IVIG)

    Dec 1, 2023, 00:00

  • HTA167 Another Hurdle in Anticancer New Drug Listing in Korea—Setting the Reimbursement Scope

    Dec 1, 2023, 00:00

  • EE24 Budget Impact of Stepping Off Patients from Long-Term Inappropriate Proton Pump Inhibitors (PPIs) Use to Episodic Alginate Treatment

    Dec 1, 2023, 00:00

  • EE507 Pre-Progression Health State Utility Values From the TALAPRO-2 Clinical Trial in Patients With Metastatic Castration-Resistant Prostate Cancer Unselected for DDR Mutations

    Dec 1, 2023, 00:00

  • HTA40 Making MCDA 'Shiny' With an Adaptive Support Tool for Healthcare Decision-Making: An Application in Broad Molecular Testing With R Shiny

    Dec 1, 2023, 00:00

  • CO23 How Immunotherapies Have Altered the Future of Cancer Treatment: Patients Living Longer, Healthier Lives

    Dec 1, 2023, 00:00

  • EE105 anti-VEGFs Use in Neovascular Age-Related Macular Degeneration: An Analysis of the National Report on Medicines Use in Italy

    Dec 1, 2023, 00:00

  • EE523 Is Dismissing Intervention Development Costs a Fallacy? a Case Study of a Digital Health Intervention E-MAT

    Dec 1, 2023, 00:00

  • HPR92 Burnt Out or Something More? Investigating Drivers of and Spatial Variation in NHS Staff Turnover Intention

    Dec 1, 2023, 00:00

  • HTA287 Impact of the 2020 Update of the French Guidelines for Economic Evaluation on the Economic Opinions Issued By the Economic Evaluation and Public Health Committee (CEESP)

    Dec 1, 2023, 00:00

  • MSR19 Disease Diagnosis and Severity Prediction: Artificial Intelligence Applications in Hemophilia A

    Dec 1, 2023, 00:00

  • EPH71 Tendencies in Hospital Burn Care for Children in Germany

    Dec 1, 2023, 00:00

  • Award Winners

    Dec 1, 2023, 00:00

  • CO60 Predicting Treatment Effects from Surrogate Endpoints in First-Line (1L) Metastatic Castration-Resistant Prostate Cancer (MCRPC)

    Dec 1, 2023, 00:00

  • MSR134 The Impact of Loneliness on Health Service Use and Health-Related Quality of Life Among Informal Carers in Australia

    Dec 1, 2023, 00:00

  • SA13 Can Models for Surrogate Endpoint Evaluation Be Used to Predict Generic Measures From Disease Specific Measures of Health Related Quality of Life Based on Summary Data?

    Dec 1, 2023, 00:00

  • EE472 Estimation of the Burden of Chronic Kidney Disease in the Argentine Health System

    Dec 1, 2023, 00:00

  • HTA170 Assessing the Impact of the NICE Methods Review on Rare Diseases

    Dec 1, 2023, 00:00

  • RWD91 Hospital Efficiency Impact of Spectral CT Versus Conventional CT in Diagnosis of Patients Suspected of Occult Cancer in the UK

    Dec 1, 2023, 00:00

  • EE385 Cost per Outcome Analysis of Osimertinib and Atezolizumab for Adjuvant Non-Small Cell Lung Cancer EGFRm Stage II-IIIA in Two Years from Brazilian Private Health System Perspective

    Dec 1, 2023, 00:00

  • EPH100 Public Health Impact of Switching from a 4-Valent to a 9-Valent HPV Vaccination Program in Mexico

    Dec 1, 2023, 00:00

  • OP29 A Comparative Study of Patient Safety Culture Between 2013 and 2019 at a University Hospital in a Rural Area in Japan

    Dec 1, 2023, 00:00

  • EE726 Economics Costs Associated with Hyperkalemia in Argentina

    Dec 1, 2023, 00:00

  • SA10 The Burden of Illness of Vasomotor Symptoms Associated with Menopause

    Dec 1, 2023, 00:00

  • HPR25 Germany: Leading the Way for Digital Health Technology Assessment in Europe

    Dec 1, 2023, 00:00

  • HSD124 Treatment Patterns in Pediatric Patients with Atopic Dermatitis

    Dec 1, 2023, 00:00

  • HTA341 Egyptian Guidelines for Pharmacoeconomic Evaluations: Toward Standardization of Drug Reimbursement Applications

    Dec 1, 2023, 00:00

  • RWD18 Characterization of Time-to-Treatment-Discontinuation (TTTD) as a Proxy for Progression-Free Survival (PFS) in Real-World Evidence (RWE) Based Analyses of Relapsed-Refractory Multiple Myeloma (RRMM)

    Dec 1, 2023, 00:00

  • PCR93 Actinic Keratosis: Patient Perceptions and Expectations for Treatment (REAKT Study)

    Dec 1, 2023, 00:00

  • RWD17 Methodology for the Development of a Data Collection Tool

    Dec 1, 2023, 00:00

  • MSR85 Psoriasis Symptoms and Impacts Measure: Identifying Key Items Reflecting Core Symptoms of Patients with Plaque Psoriasis

    Dec 1, 2023, 00:00

  • PCR62 Treatment Satisfaction and Health-Related Quality of Life in People Living With HIV Receiving DTG/3TC Who Are Treatment Experienced or Treatment Naive in Europe

    Dec 1, 2023, 00:00

  • EE352 A Budget Impact Analysis of Cladribine in England and Wales for Patients With Highly Active Relapsing-Remitting Multiple Sclerosis (HA-RRMS)

    Dec 1, 2023, 00:00

  • EE604 Cost-Effectiveness Analysis of Single-Inhaler Triple Therapy (FF/UMEC/VI) in COPD Using the Impact Trial: China Medical Insurance System Perspective

    Dec 1, 2023, 00:00

  • EPH193 The Role of Adjuvant Atezolizumab in Reducing Recurrence-Related Treatment Costs in Resected Early-Stage PD-L1 High Non-Small Cell Lung Cancer across Europe

    Dec 1, 2023, 00:00

  • EPH178 Burden of the Disease and Management in COVID-19 Hospitalized Patients in MSO and Home Care in Fran COVID-Hosp Study (2020-2022)

    Dec 1, 2023, 00:00

  • CO162 More Serbia: Molnupiravir Real World Utilization Among COVID-19 Patients in Serbia

    Dec 1, 2023, 00:00

  • CO29 Real-World Benefit of Ataluren Treatment in Milestones Not Related to Ambulatory Function in Nonsense Duchenne Muscular Dystrophy Versus Standard of Care

    Dec 1, 2023, 00:00

  • HTA179 Environmental Impact and Health Technology Assessment: State of Art and Future Perspectives

    Dec 1, 2023, 00:00

  • RWD65 Patterns of Antibiotic Prescribing in a Tertiary Hospital Using Real-World Data

    Dec 1, 2023, 00:00

  • HPR176 Exploring Diverse Health Financing Models in Europe

    Dec 1, 2023, 00:00

  • HPR44 Regional Inequalities in Access to Specialized Healthcare in the Brazilian Unified Health System

    Dec 1, 2023, 00:00

  • PCR29 Progressive Disease Milestones and Survival in Duchenne Muscular Dystrophy (DMD): A Model-Based Synthesis for Extrapolating Lifetime Treatment Effects From Clinical Trial Results

    Dec 1, 2023, 00:00

  • RWD59 Economic and Healthcare Resource Utilization by Transthyretin Amyloid Cardiomyopathy Patients in Spain: Observations From the PRACTICA Study

    Dec 1, 2023, 00:00

  • HPR158 Challenges, Opportunities and Policy Ways Forward to Systematically Embed the Use of Patient Experience Data in Healthcare Decision-Making: Insights From Multi-Stakeholder Interviews

    Dec 1, 2023, 00:00

  • HPR184 Social Determinants of Health (SDoH) and Other Predictors in Treatment Initiation with CDK4/6 Inhibitors in Medicare Patients with HR+/HER2– Metastatic Breast Cancer (MBC)

    Dec 1, 2023, 00:00

  • MSR79 Matching Plus Regression Adjustment for the Estimation of the Average Treatment Effect on Survival Outcomes: A Case Study with Mosunetuzumab in Relapsed/Refractory Follicular Lymphoma

    Dec 1, 2023, 00:00

  • HPR36 Volume Vs Value: Understanding the Pricing Dynamics of Multi-Indication Therapies in Weighted-Average List Price Markets

    Dec 1, 2023, 00:00

  • MSR156 Evaluating Bias Associated With Inadequate Variable Selection When Using Inverse Probability of Censoring Weights to Adjust for Treatment Switches in Clinical Trials

    Dec 1, 2023, 00:00

  • HTA354 Cross Analysis of HAS Conclusions Amongst Products with an Economic Opinion Posted in 2022

    Dec 1, 2023, 00:00

  • EE606 Tools for the Critical Appraisal of Health Economic Analyses: A Scoping Review

    Dec 1, 2023, 00:00

  • CO77 Impact of Imetelstat Treatment on PROs and Health Care Resource Utilization in Heavily Transfused Non-Del(5Q) Lower-Risk Myelodysplastic Syndromes Relapsed/Refractory to Erythropoiesis Stimulating Agents: IMerge Phase 3 Trial

    Dec 1, 2023, 00:00

  • EE22 Hybrid Closed Loops – A Cost-Effective Future for Type 1 Diabetes Standard of Care? An Update to the TA10845 Economic SLR

    Dec 1, 2023, 00:00

  • CO16 Effect of Daratumumab on Pneumonia in Patients with Multiple Myeloma Using Population Based Real-World Data

    Dec 1, 2023, 00:00

  • HTA249 The Use of Preprints in Health Technology Assessment during Sars-Cov-2 Pandemic

    Dec 1, 2023, 00:00

  • RWD169 Resource Utilization of Different Remission and Relapse Profiles in Chronic Urticaria—Results From Predict-CSU Real-World Study in the United States

    Dec 1, 2023, 00:00

  • HTA100 Health Technology Assessment Paradigm in Rare Diseases: Critical Determinants and Recommendations

    Dec 1, 2023, 00:00

  • CO151 Association of Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists With the Risk of Developing Dementia in People With Type 2 Diabetes Mellitus

    Dec 1, 2023, 00:00

  • EE63 Cost-Effectiveness of Olaparib Plus Bevacizumab First-Line Maintenance in Ovarian Cancer Alongside the PAOLA-1 Trial

    Dec 1, 2023, 00:00

  • CO72 Vitamin D as an Adjunct Therapy in the Treatment of Atopic Dermatitis: A Targeted Review

    Dec 1, 2023, 00:00

  • PT35 Matching-Adjusted Indirect Comparison (MAIC) of Dabrafenib Plus Trametinib Versus Pembrolizumab Plus Chemotherapy in Patients with Treatment-Naive Metastatic BRAF V600 Mutation-Positive Non-Small Cell Lung Cancer (NSCLC)

    Dec 1, 2023, 00:00

  • EE549 Systematic Review of the Cost Effectiveness of Newborn Screening for Severe Combined Immunodeficiency

    Dec 1, 2023, 00:00

  • EE499 Cost-Effectiveness Analysis of Using the Fixed-Dose Combination of Levodopa/Carbidopa/Entacapone in Patients With Parkinson’s Disease in Kazakhstan

    Dec 1, 2023, 00:00

  • EE555 Economic Burden of Cardiorespiratory Hospitalizations Associated With RSV Among US Adults, 2017-2019

    Dec 1, 2023, 00:00

  • HSD13 The Impact of Co-Locating GP-Led Minor Injury Clinic on Pediatric Emergency Department

    Dec 1, 2023, 00:00

  • MSR162 The Curse of Data Maturity in Observational Studies: Practical Advice from Protocol Development to Interpretation of Results

    Dec 1, 2023, 00:00

  • SA60 Key Challenges in Gene Therapy Development for Usher Syndrome: Insights from Machine-Assisted Rapid Scoping Review

    Dec 1, 2023, 00:00

  • HTA88 Reimbursement of CAR-T Cell Therapies in Europe: Key Challenges from Precedents and Lessons for Future

    Dec 1, 2023, 00:00

  • EPH118 Elevated Amputation Rates in Painful Diabetic Polyneuropathy: Insights from a Real-World Large Payer Data Set

    Dec 1, 2023, 00:00

  • HTA177 The Safety and Effectiveness of Root Membrane Technique (Socket Shield Technique)

    Dec 1, 2023, 00:00

  • HTA258 A Hospital-Based Health Technology Assessment of Near-Infrared Fluorescence Using Indocyanine Green for Sentinel Lymph Node Mapping for Breast Cancer and Gynecologic Cancer

    Dec 1, 2023, 00:00

  • PCR164 Feasibility and Validation of the Japanese Version of the EQ-HWB

    Dec 1, 2023, 00:00

  • MSR26 The Use of Copilot, a Generative Artificial Intelligence Tool, as VBA Programming Assistant in Excel-Based Health Economic Models

    Dec 1, 2023, 00:00

  • EE484 Multinational Real-World Data in Transplant Patients with Refractory/Resistant Cytomegalovirus Infection Enhance Cost-Effectiveness Modelling Outcomes

    Dec 1, 2023, 00:00

  • CO57 A New Approach in Network Meta-Analysis Using Blended Survival Curves to Extrapolate Long-Term Survival from Immature Data

    Dec 1, 2023, 00:00

  • HPR131 What Is a Year of Life Worth? Empirical Findings from Worldwide Economic Studies on the Value of a Statistical Life

    Dec 1, 2023, 00:00

  • HTA261 Preparing for the EU Regulation on HTA and Joint Clinical Assessments of Vaccines

    Dec 1, 2023, 00:00

  • PCR8 Perceived Barriers to HIV Prevention and Detection Among Adolescents and Young People, According to Civil Organization Leaders and Health Professionals in Chile

    Dec 1, 2023, 00:00

  • Challenges in Modeling Oncology Outcomes

    Dec 1, 2023, 00:00

  • HPR38 Arbitral Awards on Reimbursement Prices Since 2019 in Germany: What We Can Learn?

    Dec 1, 2023, 00:00

  • PCR168 Diabetes Mellitus Type 1 in Chile: Unveiling the Patient Journey Throughout Coverage Schemes in Young People and Adults

    Dec 1, 2023, 00:00

  • OP22 Content Analysis of Drug Recall Announcements in Saudi Arabia: Between 2016 and 2022

    Dec 1, 2023, 00:00

  • HTA134 The Impact of Non-Comparative Data for Non-Orphan Drugs on HTA and Pricing Outcomes in Germany: Can an Added Benefit Ever be Proven?

    Dec 1, 2023, 00:00

  • MT59 Overview of Approved Digital Therapeutics in Belgium

    Dec 1, 2023, 00:00

  • EE299 The Absence of Risk Preferences in Health Economics – What Can We Learn From Transport Economics?

    Dec 1, 2023, 00:00

  • EPH82 Real-World Outcomes in Patients with Resected Non-Small Cell Lung Cancer (NSCLC) Receiving (NEO)Adjuvant Treatment in Germany: An I-O Optimise Analysis

    Dec 1, 2023, 00:00

  • EE83 Cost-Utility and Budget Impact Analyses of Cervical Cancer Screening Using Self-Collected Sample Kit for HPV DNA Testing in Thailand

    Dec 1, 2023, 00:00

  • EPH119 Disease Burden and Cost-of-Illness of Hepatocellular Carcinoma in Portugal: A Model-Based Analysis Considering the Barcelona Clinic Liver Cancer Disease Staging and Treatment Algorithm System

    Dec 1, 2023, 00:00

  • HTA137 Determining Relevant Thresholds for Reimbursement of Healthcare Interventions: Should We Prohibit the Use of the QALY at Last?

    Dec 1, 2023, 00:00

  • EE345 Clinical and Economic Impact Analysis of Viscosupplementation With Hylan G-F 20 Versus Hyaluronic Acid for the Treatment of Knee Osteoarthrosis in Colombia

    Dec 1, 2023, 00:00

  • MSR125 How Prognostic Factors Are Identified for Population Matching Analysis

    Dec 1, 2023, 00:00

  • HTA356 Bridging the Gap between National and EUNETHTA21 HTA Methods. Are Marketing Authorisation Holders Ready for Joint Clinical Assessments?

    Dec 1, 2023, 00:00

  • PCR135 Selecting Preference-Based Measures (PBMS) for Pediatric Studies: A Proposed Decision Making Framework

    Dec 1, 2023, 00:00

  • HPR100 Orphan Drugs in Algeria and Six Other Countries: A Cross Comparison Study

    Dec 1, 2023, 00:00

  • EE194 Economic Evaluation of Tofacitinib for the Treatment of Active Polyarticular Juvenile Idiopathic Arthritis in Greece

    Dec 1, 2023, 00:00

  • EE611 Economic Evaluation of Person-Centred Care Using a Digital Platform and Structure Telephone Support for People with Chronic Heart Failure and/or Chronic Obstructive Pulmonary Disease

    Dec 1, 2023, 00:00

  • SA53 The Accuracy of Network Meta-Analysis Feasibility Predictions Based on Data Included Only in the Abstracts of Trial Publications

    Dec 1, 2023, 00:00

  • EPH93 Progression From Cutaneous to Systemic Lupus Erythematosus: A Systematic Literature Review

    Dec 1, 2023, 00:00

  • HPR132 The Role of Economic Evaluation in HTA in Spain

    Dec 1, 2023, 00:00

  • EE289 Comparison of the Clinical and Economic Impact of Two COVID-19 mRNA Vaccines in High Risk Individuals in the Tokyo Prefecture

    Dec 1, 2023, 00:00

  • EE704 Risdiplam for the Treatment of Spinal Muscular Atrophy: Impact on the National Healthcare Service During the First 15 Months of Commercialization in Italy

    Dec 1, 2023, 00:00

  • RWD7 Graphical Representation of Real-World Data for Analysing Infection Outbreaks Within a Tertiary Hospital Setting: A Data-Driven Approach

    Dec 1, 2023, 00:00

  • CO27 The Feasibility of Systematic Goal Quality Assurance During Goal Attainment Scaling in a Rare Disease

    Dec 1, 2023, 00:00

  • RWD151 Evaluation of the Effect of Methodological Assumptions on Estimates of Adherence to Antipsychotics: A Real-World Data Study

    Dec 1, 2023, 00:00

  • EE39 Loss of Productivity, Use of Healthcare Resources and Cost Associated with Insomnia

    Dec 1, 2023, 00:00

  • CO173 Outcomes, Treatment Pattern, and Related Cost of Late-Stage Non-Small Cell Lung (NSCLC) Cancer in Taiwan

    Dec 1, 2023, 00:00

  • EPH116 Patient Pathways and Economics of Tumor-Related Hypothalamic Obesity in Germany—A Representative Claims Data Analysis

    Dec 1, 2023, 00:00

  • HTA355 A Roadmap Towards Implementing HTA in Oman

    Dec 1, 2023, 00:00

  • CO21 Matching Adjusted Indirect Comparison (MAIC) of Selpercatinib Vs Cabozantinib in RET Mutation-Positive Advanced Medullary Thyroid Cancer (MTC)

    Dec 1, 2023, 00:00

  • HTA140 The in Need of Medicines Fund: Analysis of NICE Technology Appraisals to Explore Barriers to Managed Access Via the IMF

    Dec 1, 2023, 00:00

  • PCR177 Assessing the Impact of Relapses on Patient Outcomes in NMOSD

    Dec 1, 2023, 00:00

  • EE68 Cost-Effectiveness of Second-Line Treatment for Advanced Endometrial Carcinoma in Taiwan: Lenvatinib Plus Pembrolizumab Versus Doxorubicin

    Dec 1, 2023, 00:00

  • EE33 Targeted Literature Review on the Economic and Quality of Life Burden Caused by Acne

    Dec 1, 2023, 00:00

  • EE48 Healthcare Resource Utilization (HCRU), Quality of Life (QoL), and Employment Changes for Early, Middle and Late-Stage People with Amyotrophic Lateral Sclerosis (pALS) in Italy: Results from a Real-World Survey

    Dec 1, 2023, 00:00

  • HPR4 Transferable Exclusivity Vouchers: A Silver Bullet?

    Dec 1, 2023, 00:00

  • HSD92 Factors Having an Impact on the Prescription of Cancer Treatments in Hospital at Home Program in Bronchopulmonary Cancer: A French Claims Database Analysis (2016-2021)

    Dec 1, 2023, 00:00

  • HTA286 Challenges and Solutions to Estimating Environmental Impact in Health Technology Assessment

    Dec 1, 2023, 00:00

  • EE6 Expected Value of Perfect Implementation of Icosapent Ethyl (Vazkepa) in Sweden

    Dec 1, 2023, 00:00

  • PCR71 Using Schedule for the Evaluation of Individual Quality of Life (SEIQoL) and Computer Adapted Testing (CAT) in Current Practices

    Dec 1, 2023, 00:00

  • PCR240 Incorporating a Holistic Patient Perspective When Assessing the Value of Non-Small Cell Lung Cancer (NSCLC) Therapies

    Dec 1, 2023, 00:00

  • HTA68 Trends in Northern Ireland HTA Guidance Adoption: NICE Shows Dominance over SMC and AWMSG

    Dec 1, 2023, 00:00

  • P20 Matching-Adjusted Indirect Treatment Comparison (MAIC) of Teclistamab Vs Belantamab Mafodotin for the Treatment of Patients with Triple-Class Exposed (TCE) Relapsed/Refractory Multiple Myeloma (RRMM)

    Dec 1, 2023, 00:00

  • PCR165 Accessibility Vs Standardization: A Study of Electronic Implementation of Patient-Reported Outcomes Measures with Vision-Impaired Participants

    Dec 1, 2023, 00:00

  • EE489 Healthcare Utilization and Costs Among Treatment-Experienced Medicaid Beneficiaries Utilizing Single-Treatment Versus Multi-Treatment Regimens for HIV

    Dec 1, 2023, 00:00

  • HTA244 Evaluation of the Acceptance of Real-World Evidence (RWE) in Eunethta Joint Clinical Assessments (JCA) to Support Evidence for Reimbursement Decisions

    Dec 1, 2023, 00:00

  • CO50 Imminent Recurrent Fracture Risk in Patients with Osteoporotic Fractures: A Nationwide Cohort Study in South Korea

    Dec 1, 2023, 00:00

  • RWD31 The Impact of Advanced Training on Operational Efficiency in Robotic-Assisted Rectal Resection

    Dec 1, 2023, 00:00

  • EPH75 Adverse Event Types and Discontinuation Rate of Alzheimer's Medication Approved by United States Food and Drug Administration (USFDA)

    Dec 1, 2023, 00:00

  • PT8 Five-Year Healthcare Resource Consumption and Direct Costs of Women with a New Diagnosis of Hr+/HER2- Breast Cancer Primary or Advanced: Analysis of a Large Italian Administrative Database

    Dec 1, 2023, 00:00

  • RWD22 Economic Burden of Moderate and Severe Hemophilia A and B in Spain, Real-World Evidence Insights from the Cost of Hemophilia in Europe: A Socio-Economic Survey II (CHESS II) Study

    Dec 1, 2023, 00:00

  • EE450 Evaluating Price Trends in Supplements from 2018 to 2022 in Turkiye

    Dec 1, 2023, 00:00

  • MSR27 Inter-Reviewer Reliability of Literature Screening and Data Extraction for Human and Machine-Assisted Systematic Reviews

    Dec 1, 2023, 00:00

  • EPH262 The Preparedness and Contribution of Community Pharmacists During Public Health Crises

    Dec 1, 2023, 00:00

  • HPR183 Evaluating the Saving Potential of Lenalidomide Before and After Transition to the Reference Price System in Finland

    Dec 1, 2023, 00:00

  • RWD105 Identifying and Appraising Fit-for-Purpose Data Sources for Real World Evidence Studies: A Structured Approach to Conducting Data Source Feasibility Assessments

    Dec 1, 2023, 00:00

  • HSD3 Treatment and Associated Outcomes of Type-2 Diabetes Mellitus Patients With a Cardiovascular Comorbidity and Comparison With Guideline Recommendations: A German Claims Data Analysis

    Dec 1, 2023, 00:00

  • RWD88 Investigating the Transferability, at the National Level, of Results from Hemsys, a French Multidisciplinary Concertation Meetings Database in Onco-Hematology, to Generate Real-World Evidence

    Dec 1, 2023, 00:00

  • PCR58 Social Media Research to Understand Reported Efficacy of GLP-1 RAs for Weight Loss

    Dec 1, 2023, 00:00

  • EE71 Cost-Effectiveness Analysis of Using Foundationone Liquid CDx in Patients With Advanced Non-Small Cell Lung Cancer in Whom Tissue-Based Testing Is Not Feasible

    Dec 1, 2023, 00:00

  • EE179 Economic Burden and Health-Related Quality of Life Among Older People With Dementia Living at Home and Their Informal Caregivers in the Milan Metropolitan Area

    Dec 1, 2023, 00:00
  • «
  • 11
  • 12 (current)
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • »